Dear Dr. Hermann:

Please refer to your supplemental new drug application dated December 4, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Tracleer (bosentan) 62.5 and 125 mg Tablets.

We acknowledge receipt of your submissions dated December 19, 2002 and May 27 and 28 and September 22, 2003.

This supplemental new drug application provides for revisions to the CLINICAL PHARMACOLOGY, PRECAUTIONS, ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION sections of the approved package insert and the Medication Guide. In addition, the Medication Guide has been added to the end of the package insert.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert and Medication Guide.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated “FPL for approved supplement NDA 21-290/S-001.” Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must submit patent information on form FDA 3542, Patent Information Submitted Upon and After Approval of an NDA or Supplement, within 30 days of the date of this letter as required by 21 CFR 314.53(c)(2)(ii) and 314.53(d)(2) at the address provided by 21 CFR 314.53(d)(4). The form may be obtained at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html. To expedite review of this patent declaration form, we request you submit an additional copy of the form to this application and to the Center for Drug Evaluation and Research “Orange Book” staff at
In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Cardio-Renal Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Ms. Melissa Robb
Regulatory Health Project Manager
(301) 594-5313

Sincerely,

{See appended electronic signature page}

Douglas C. Throckmorton, M.D.
Director
Division of Cardio-Renal Drug Products
Office for Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure
CC:
Actelion Ltd.
Attention: Tom Lategan, Ph.D.
56 Huckleberry Lane
North Andover, MA 01845
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Doug Throckmorton
10/6/03 02:08:43 PM